Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Uric acid sodium 是氧自由基 (oxygen radical) 的清除剂,是一种有效的、常见的抗氧化剂,有助于维持机体血压稳定和抗氧化应激。Uric acid sodium 能清除活性氧 (ROS),如单线态氧和过氧亚硝酸盐,对脂质过氧化有抑制作用,与痛风性关节病的发病机理和草酸钙结石的形成有关。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 113 | 现货 | ||
50 mg | ¥ 145 | 现货 | ||
100 mg | ¥ 273 | 现货 | ||
200 mg | ¥ 413 | 5日内发货 | ||
500 mg | ¥ 678 | 5日内发货 |
产品描述 | Uric acid sodium, scavengers of oxygen radicals, is a potent and common antioxidant that helps maintain stable blood pressure and resist oxidative stress. Uric acid sodium, which removes reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, has an inhibitory effect on lipid peroxidation and is associated with the pathogenesis of gout joint disease and the formation of calcium oxalate stones. |
体外活性 | Uric acid, when administered at a concentration of 400 μM for 48 hours, offers protection to Caco-2 cells by preventing indomethacin-induced lipid peroxidation [2]. Furthermore, co-treatment of cells with indomethacin and uric acid sodium (200 μM indomethacin plus 400 μM uric acid; 24 hours) significantly reduces reactive oxygen species (ROS) levels compared to cells treated with indomethacin alone. Additionally, cell viability in Caco-2 cells exposed to both indomethacin and uric acid sodium (200 μM indomethacin plus 400 μM uric acid; 24 hours) is higher compared to cells treated solely with indomethacin. The protective effect of uric acid sodium on indomethacin-induced changes in intestinal cells is attributed to its antioxidant activity [2]. |
体内活性 | Oral treatment of uric acid sodium at a dosage of 250 mg/kg has a beneficial effect on indomethacin-induced enteropathy. It ameliorates the enteropathy caused by indomethacin. Oral treatment of uric acid sodium leads to a reduction in ROS accumulation in the ileum in a mouse model of indomethacin-induced enteropathy [2]. |
分子量 | 190.09 |
分子式 | C5H3N4NaO3 |
CAS No. | 1198-77-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2.8 mg/mL (14.8 mM), when pH is adjusted to 4 with HCl. Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.2607 mL | 26.3033 mL | 52.6067 mL | 131.5167 mL |
5 mM | 1.0521 mL | 5.2607 mL | 10.5213 mL | 26.3033 mL | |
10 mM | 0.5261 mL | 2.6303 mL | 5.2607 mL | 13.1517 mL |
中药材名称 | 中药材拉丁名 | 性 | 味 | 归经 |
穿龙薯蓣 | Dioscorea nipponica Makino. | 平 | 苦 | 肝, 肺 |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Uric acid sodium 1198-77-2 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species Monosodium urate Inhibitor inhibitor inhibit